Lessons for the clinical nephrologist: legacy effects of bevacizumab and ramucirumab lead to nephrotic syndrome due to renal-limited thrombotic microangiopathy with podocytopathy

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate

Informed consent was obtained from the patient in this case.

Consent to publish

The patient provided written consent for their personal or clinical information to be published in this report, along with any accompanying images.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of interest

The authors have declared that no conflict of interest exists.

Funding

This study did not receive any financial support.

Authors’ contribution

Takahide Iwasaki and Masataka Ikeda diagnosed and treated nephrotic syndrome. Akihiro Kuma and Makoto Yoshida diagnosed the renal pathology. Takahide Iwasaki drafted the manuscript. Akihiro Kuma, Masataka Ikeda, and Takahiro Kuragano revised the manuscript critically. All authors read and approved the final manuscript.

留言 (0)

沒有登入
gif